Moderna says Covid-19 boosters stand a fighting chance against new variants
A day before its second annual Vaccines Day, Moderna has posted an update on its crown jewel, including a 6-month look at the Covid-19 shot and new preclinical data that suggest its booster candidates stand a fighting chance against new variants.
Moderna’s variant-specific booster mRNA-1273.351, which was designed to target the B.1.351 mutation first identified in South Africa, “closed the neutralizing titer gap for variants of concern” in mice, the company said on Tuesday afternoon. When given at the 6-month mark, the booster elicited neutralizing titers against the variant that were comparable to those produced against the original virus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
